PURPOSE: To sensitize non-small cell lung cancer (NSCLC) to radiotherapy by tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. EXPERIMENTAL DESIGN: The TRAIL was delivered to human NSCLC cell lines and normal human bronchial epithelial cells by the replication-defective adenoviral vector Ad/TRAIL-F/RGD using a tumor-specific human telomerase reverse transcriptase promoter. Cancer growth was studied using 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt and clonogenic assays. Activation of the apoptosis pathway was analyzed in a Western blot and sub-G(1) DNA accumulation. A xenograft mouse lung cancer model was treated by intratumoral injections of Ad/TRAIL-F/RGD and local radiotherapy; the other groups received one of these treatments alone or a control agent. Apoptosis and TRAIL expression in tumors were also analyzed. RESULTS: Ad/TRAIL-F/RGD specifically targets human NSCLC cells without significant effect in normal human bronchial epithelial cells. The combination of Ad/TRAIL-F/RGD and radiotherapy significantly improved cell-killing effect in all NSCLC cell lines tested (P < 0.05). Expression of TRAIL showed a dose-dependent relationship with Ad/TRAIL-F/RGD, and radiation seemed to increase TRAIL expression. Activation of the apoptosis by TRAIL and radiation was shown by activation of caspase-9, caspase-8, caspase-3, and poly(ADP-ribose) polymerase and increased DNA sub-G(1) accumulation. The combination of TRAIL and radiotherapy significantly increased apoptosis in vivo, inhibited tumor growth, and prolonged mean survival in mice bearing human NSCLC to 43.7 days compared with 23.7 days (TRAIL only) and 16.5 days (radiotherapy only; P < 0.05). CONCLUSIONS: The combination of Ad/TRAIL-F/RGD and radiotherapy significantly improved therapeutic efficacy in suppressing NSCLC tumor growth and prolonging survival. Ad/TRAIL-F/RGD may improve the therapeutic ratio of radiotherapy in NSCLC.
PURPOSE: To sensitize non-small cell lung cancer (NSCLC) to radiotherapy by tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. EXPERIMENTAL DESIGN: The TRAIL was delivered to humanNSCLC cell lines and normal human bronchial epithelial cells by the replication-defective adenoviral vector Ad/TRAIL-F/RGD using a tumor-specific human telomerase reverse transcriptase promoter. Cancer growth was studied using 2,3-bis[2-methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt and clonogenic assays. Activation of the apoptosis pathway was analyzed in a Western blot and sub-G(1) DNA accumulation. A xenograft mouselung cancer model was treated by intratumoral injections of Ad/TRAIL-F/RGD and local radiotherapy; the other groups received one of these treatments alone or a control agent. Apoptosis and TRAIL expression in tumors were also analyzed. RESULTS: Ad/TRAIL-F/RGD specifically targets humanNSCLC cells without significant effect in normal human bronchial epithelial cells. The combination of Ad/TRAIL-F/RGD and radiotherapy significantly improved cell-killing effect in all NSCLC cell lines tested (P < 0.05). Expression of TRAIL showed a dose-dependent relationship with Ad/TRAIL-F/RGD, and radiation seemed to increase TRAIL expression. Activation of the apoptosis by TRAIL and radiation was shown by activation of caspase-9, caspase-8, caspase-3, and poly(ADP-ribose) polymerase and increased DNA sub-G(1) accumulation. The combination of TRAIL and radiotherapy significantly increased apoptosis in vivo, inhibited tumor growth, and prolonged mean survival in mice bearing humanNSCLC to 43.7 days compared with 23.7 days (TRAIL only) and 16.5 days (radiotherapy only; P < 0.05). CONCLUSIONS: The combination of Ad/TRAIL-F/RGD and radiotherapy significantly improved therapeutic efficacy in suppressing NSCLC tumor growth and prolonging survival. Ad/TRAIL-F/RGD may improve the therapeutic ratio of radiotherapy in NSCLC.
Authors: Stephen G Swisher; Jack A Roth; Ritsuko Komaki; Jian Gu; J Jack Lee; Marshall Hicks; Jae Y Ro; Waun K Hong; James A Merritt; Kamaran Ahrar; N Edward Atkinson; Arlene M Correa; Marcelo Dolormente; Linda Dreiling; Adel K El-Naggar; Frank Fossella; Rhodette Francisco; Bonnie Glisson; Susan Grammer; Roy Herbst; Armando Huaringa; Bonnie Kemp; Fadlo R Khuri; Jonathan M Kurie; Zhongxio Liao; Timothy J McDonnell; Rudolfo Morice; Frank Morello; Reginald Munden; Vassiliki Papadimitrakopoulou; Katherine M W Pisters; Joe B Putnam; Arcenio J Sarabia; Thomas Shelton; Craig Stevens; Daniel M Shin; William R Smythe; Ara A Vaporciyan; Garrett L Walsh; Min Yin Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun Journal: CA Cancer J Clin Date: 2004 Jan-Feb Impact factor: 508.702
Authors: Diana C J Spierings; Elisabeth G E de Vries; Wim Timens; Harry J M Groen; H Marike Boezen; Steven de Jong Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: Xiaochun Zhang; Steven H Lin; Bingliang Fang; Michael Gillin; Radhe Mohan; Joe Y Chang Journal: J Thorac Oncol Date: 2013-12 Impact factor: 15.609
Authors: Rajas V Warke; Katherine J Martin; Kris Giaya; Sunil K Shaw; Alan L Rothman; Irene Bosch Journal: J Virol Date: 2007-10-03 Impact factor: 5.103